Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Lyme Disease - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Lyme Disease - Pipeline Review, H2 2014', provides an overview of the Lyme Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lyme Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lyme Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Lyme Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lyme Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lyme Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lyme Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lyme Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lyme Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lyme Disease Overview 6 Therapeutics Development 7 Pipeline Products for Lyme Disease - Overview 7 Pipeline Products for Lyme Disease - Comparative Analysis 8 Lyme Disease - Therapeutics under Development by Companies 9 Lyme Disease - Therapeutics under Investigation by Universities/Institutes 10 Lyme Disease - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Lyme Disease - Products under Development by Companies 14 Lyme Disease - Products under Investigation by Universities/Institutes 15 Lyme Disease - Companies Involved in Therapeutics Development 16 Baxter International Inc. 16 VG Life Sciences, Inc. 17 LondonPharma Ltd 18 Valneva SE 19 Lyme Disease - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 azithromycin gel - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Multivalent Recombinant OspA Lyme Borreliosis Vaccine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecule for Lyme Disease - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 IC-15 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 VGV-L - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 lyme disease vaccine 2 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Subunit Vaccine for Lyme Disease - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Lyme Disease - Recent Pipeline Updates 35 Lyme Disease - Dormant Projects 37 Lyme Disease - Product Development Milestones 38 Featured News & Press Releases 38 Mar 07, 2012: Viral Genetics Submits Pre-IND Document For Lyme Disease Drug Candidate To FDA 38 Oct 21, 2008: Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study and Team Receives Positive Feedback at ILADS Conference, Study Model Potentially Applies to HIV/AIDS and Other Immune Based Diseases. 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables Number of Products under Development for Lyme Disease, H2 2014 7 Number of Products under Development for Lyme Disease - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Lyme Disease - Pipeline by Baxter International Inc., H2 2014 16 Lyme Disease - Pipeline by VG Life Sciences, Inc., H2 2014 17 Lyme Disease - Pipeline by LondonPharma Ltd, H2 2014 18 Lyme Disease - Pipeline by Valneva SE, H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 26 Lyme Disease Therapeutics - Recent Pipeline Updates, H2 2014 35 Lyme Disease - Dormant Projects, H2 2014 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
